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OBJECTIVES: The aims of the current study were 1) to evaluate the reliability and validity of the Brazilian version
of the 15-item Myasthenia Gravis Quality of Life Scale and 2) to investigate the quality of life of Brazilian
patients with myasthenia gravis and its determinants.
METHODS: This cross-sectional study included 69 patients with myasthenia gravis who underwent neurological
evaluation and completed questionnaires regarding quality of life (the 36-item Short Form of the Medical
Outcomes Study and the 15-item Myasthenia Gravis Quality of Life Scale), anxiety and depressive symptoms.
RESULTS: The Brazilian version of the 15-item Myasthenia Gravis Quality of Life Scale showed high internal
consistency and good concurrent validity with the 36-item Short Form of the Medical Outcomes Study and its
subscales. Determinants of quality of life in Brazilian patients with myasthenia gravis included the current status
of myasthenia gravis as assessed by the Myasthenia Gravis Composite, the current prednisone dose and the
levels of anxiety and depression.
CONCLUSION: The Brazilian version of the 15-item Myasthenia Gravis Quality of Life Scale is a valid instrument.
Symptom severity, prednisone dosage and anxiety and depression levels impact the quality of life of patients
with myasthenia gravis.
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’ INTRODUCTION
Myasthenia gravis (MG) is characterized by fluctuating
muscle weakness and fatigability, with great inter- and intra-
individual variability (1-3). Due to its fluctuating course and
clinical heterogeneity, the optimal approach to objectively
evaluate the clinical profile, impact and treatment outcomes
of MG has been discussed (4).
Measures of quality of life (QoL) have been widely used to
follow patients with neuromuscular disorders, including MG
(5). Tracking a disease via assessment of patients’ perception
of QoL may improve their care by promoting greater
adherence to treatment and, ultimately, by leading to better
clinical control and outcome (6,7).
Several studies have investigated the QoL of MG patients.
Past studies employed the 36-item Short Form of the Medical
Outcomes Study (SF-36), a non-disease-specific tool that
assesses health-related QoL. However, SF-36 contains items
not necessarily relevant to MG (e.g. bodily pain) and does not
evaluate domains that are meaningful to MG (e.g. problems
with vision, eating and speaking). Despite these limitations,
QoL studies of MG patients that used the SF-36 demon-
strated that patients with MG differed from healthy controls
in all domains of SF-36, particularly in the rolephysical
subscale (8,9). In addition, QoL scores modestly correlate
with disease status among MG patients (8).
In 2008, a 60-item QoL questionnaire specific for MG (MG-
QOL60) was developed and validated (10). This 60-item disease-
specific instrument assesses the domains of mobility, symptoms,
emotional well-being, general contentment, thinking and fatigue,
family/social well-being, and additional concerns. However, as
the authors themselves noted, a potential limitation of MG-
QOL60 was the time required to complete the questionnaire.
Accordingly, a 15-item MG-specific QoL scale (MG-QOL15) was
recently developed from the MG-QOL60 as a more user-
friendly instrument (11-13). The correlation coefficients for theDOI: 10.6061/clinics/2016(07)03
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associations of the scale score with disease severity and quality
of life were similar between MG-QOL15 and MG-QOL60 and
MG-QOL15 outperformed SF-36, notably by demonstrating a
stronger correlation with changes in disease severity and in
activities of daily living. MG-QOL15 also demonstrated long-
itudinal construct validity and test-retest reliability (12,13).
Most studies of the QoL of patients with MGwere conducted
in the United States and Europe, and there are scarce data on
this topic from developing countries. Recently, we translated
and adapted the Brazilian-Portuguese version of the MG-
QOL15 (14). The aim of the current study was to evaluate the
reliability and validity of MG-QOL15 in a clinical setting.
Furthermore, we aimed to identify factors associated with
perceived QoL among Brazilian patients with MG.
’ PATIENTS AND METHODS
Patients
This was a cross-sectional study that investigated MG
patients receiving attention at the Center for Neuromuscular
Diseases, University Hospital, Universidade Federal de
Minas Gerais, Belo Horizonte, Brazil. Socio-demographic
and clinical information was obtained via clinical evaluation
and chart review.
Diagnosis of MG was based on the following criteria:
clinical history of fatigability with recovery after resting,
clinical response to the administration of anticholinesterase
drugs, presence of autoantibodies and/or decreased elec-
trical activity upon repetitive nerve stimulation and exclu-
sion of alternative neurological diagnoses (15).
Clinical instruments
The Myasthenia Gravis Composite (MGC) was used to
assess the current status of MG (16). The MGC comprises
10 items evaluating ocular (3 items), bulbar (3 items),
respiratory (1 item), neck (1 item), and limb (2 items) signs
and symptoms. Patients were classified according to the
Clinical Classification of the Myasthenia Gravis Foundation
of America (MGFA) (15). This classification was developed to
identify subgroups of patients with MG who share similar
clinical features, possibly indicating similar prognoses and/
or therapeutic responses. The MGFA classification system
separates patients with purely ocular involvement from
those with generalized or bulbar muscle weakness and
categorizes the degree of weakness as mild, moderate or
severe (17).
MG-QOL15 has a maximum score of 60, and there is no
pre-specified cutoff for classifying the QoL of MG patients
(12). The higher the MG-QOL15 score, the poorer the QoL of
the MG patient. In this study, we used the Brazilian-
Portuguese version of MG-QOL15 (14), and SF-36 was used
to assess the concurrent validity of this version of MG-
QOL15.
SF-36 is a multidimensional questionnaire composed of
36 items that provide information related to eight domains of
health: physical functioning (PF), role-physical (RP), bodily
pain (BP), general health (GH), vitality (VT), social function-
ing (SF), role-emotional (RE) and mental health (MH). The
two summary measures are the physical health and mental
health components. The calculation of the physical health
component score positively weights the PF, RP, BP and GH
domain scores and negatively weights the RE and MH
domain scores. Conversely, to calculate the mental health
component score, positive weights are placed on the MH,
RE, SF and VT domain scores, whereas substantial negative
weights are placed on the PF and RP domain scores. The
total scores for each of the eight domains are converted to a
0-100 scale, with a higher score representing better health
(18). SF-36, which has previously been validated in Brazil
(19), is the most commonly used QoL instrument nation-
wide. Here, SF-36 was considered as the gold standard for
construct validation of MG-QOL15 (11-13).
Variables that may impact QoL in MG patients include
the following: a) demographic variables: age and gender;
b) clinical variables: disease duration, main symptoms, MG
classification, and treatments; and c) anxiety and depressive
symptoms. The Hospital Anxiety and Depression (HAD)
scale was used to evaluate the presence and/or severity of
anxiety and depressive symptoms (20).
Procedure
The local ethics committee approved this study, and all
patients signed a written consent form. Participants com-
pleted MG-QOL15, SF-36 and the HAD questionnaire and
underwent a neurological examination (MGC) on the day of
their routine neurological appointment. Medical records of
the patients were also revised to classify the disease
according to the MGFA system.
Statistical Analysis
To evaluate the item-specific internal consistency of MG-
QOL15, we calculated Cronbach’s alpha coefficients and
corrected the item-total correlations. A Cronbach’s alpha
between 0.60 and 0.70 indicates acceptable reliability, and
Table 1 - Characteristics of the studied myasthenia gravis
patients.
Characteristics Patients (69)
N or
Mean ± SD
% or
Median (range)
Sex
Male 14 20.3
Female 55 79.7
Age (years) 44.5±10 45 (22-68)
Educational level (years of schooling) 8.6±2.5 8 (4-13)
Disease duration 14.5±10.5 12 (1-39)
Main symptom
Ocular 23 33.3
Bulbar 21 30.4
Generalized 25 36.2
MGFA Classification
I 13 18.8
IIA 14 20.3
IIB 2 2.9
IIIA 12 17.4
IIIB 7 10.1
IVA 4 5.8
IVB 3 4.3
V 14 20.3
MGC 7.5±5 6 (0-23)
HAD Anxiety subscale score 7.7±3.2 7 (2-16)
HAD Depression subscale score 4.6±4.4 3 (0-17)
Thymectomized 42 60.9
Pyridostigmine 58 84.1
Prednisone 44 63.8
Azathioprine 30 43,5
Other immunosuppressant 9 13
SD: standard deviation; MGFA: Myasthenia Gravis Foundation of America;
HAD: Hospital Anxiety and Depression; MGC: Myasthenia Gravis
Composite.
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a value above 0.80 indicates good reliability. Pearson’s
correlation coefficients were used to evaluate concurrent
validity between MG-QOL15 and subscales of SF-36.
All continuous data are expressed as means and standard
deviations (SDs). The Mann-Whitney test was used to
compare continuous variables between two groups, and
the Kruskal-Wallis test was used to compare more than two
groups. Correlations were assessed using Pearson’s correla-
tion coefficients or Spearman’s correlation coefficients
according to the data distribution. Factors with correlations
showing statistical significance (po0.05) based on univariate
analysis were included in a multivariate linear regression
analysis to identify factors independently affecting the QoL
of MG patients. Regression tree analysis was performed to
examine the influence of each factor on QoL. A value of
po0.05 was considered statistically significant.
Statistical analyses were performed using SPSS, version
18.0 (SPSS Inc., Chicago, Illinois).
’ RESULTS
Most participants were female and middle aged (Table 1).
Regarding disease, most participants were classified as Class
IIA or V (n=14 for each), followed by Class I (n=13) and IIIA
(n=12). Regarding treatment, most patients were using
pyridostigmine and two-thirds of the patients were using
prednisone.
MG-QOL15 showed good internal consistency (Table 2).
Most items displayed a good item-total correlation, with the
exception of item 10. MG-QOL15 scores negatively corre-
lated with SF-36 scores and with the scores of most of its
subscales (Table 3). The score for the pain domain of SF-36
was the only subscale that did not correlate with the MG-
QOL15 score.
The mean MG-QOL15 score was 23.8; this value suggests
that the MG patients generally reported a good perceived
QoL. This result was corroborated by a mean SF-36 score
99.3. Regarding the physical health component, the mean
subscale scores were below 55. Regarding the mental health
component, the mean subscale scores were above 60, except
for the MH domain score.
The current status of MG (MGC; rho=0.60, po0.01), the
dosage of prednisone (rho=0.36, p=0.02) and the levels of
anxiety (rho=0.38, po0.01) and depression (rho=0.45,
po0.01) negatively correlated with QoL based on univariate
analysis (Table 4). Those four variables were included in a
Table 2 - Mean score and internal reliability of the Brazilian-Portuguese version of MG-QOL15.
Questions: Mean Median Corrected
item-total
correlation
Cronbach ’s alpha
coefficient if the
item is removed
(SD) (range) (aC)
1. I’m frustrated by my myasthenia
gravis.
1. Eu estou frustrado por causa da Miastenia
Gravis.
1.3 (1.5) 1 (0-4) 0.81 0.74
2. I have trouble using my eyes
because of my myasthenia gravis.
2. Eu tenho dificuldade para usar meus olhos por
causa da Miastenia Gravis.
1.4 (0.9) 2 (0-3) 0.78 0.75
3. I have trouble eating because of
my myasthenia gravis.
3. Eu tenho dificuldade para comer por causa da
Miastenia Gravis.
1.6 (0.9) 2 (0-4) 0.81 0.75
4. I have limited my social activity
because of my myasthenia gravis.
4. Eu limitei a minha atividade social por causa da
Miastenia Gravis.
1.6 (1.2) 1 (0-3) 0.89 0.74
5. My myasthenia gravis limits my
ability to enjoy hobbies and
activities.
5. A Miastenia Gravis limita minha capacidade de
ter divertimento e atividades de lazer.
1.9 (0.9) 2 (0-4) 0.92 0.75
6. I have trouble meeting the needs
of my family because of my
myasthenia gravis.
6. Eu tenho dificuldade para atender as
necessidades da minha famı´lia por causa da
Miastenia Gravis.
1.9 (1) 2 (0-4) 0.85 0.75
7. I have to make plans around my
myasthenia gravis.
7. Eu tenho que fazer os meus planos em torno da
Miastenia Gravis.
2 (1) 2 (0-4) 0.80 0.75
8. My occupational skills and job
status have been negatively affected
by my myasthenia gravis.
8. Minhas habilidades profissionais e minha
posic¸a˜o no trabalho (cargo) foram afetadas
negativamente por causa da Miastenia Gravis.
2.1 (1.1) 2 (0-4) 0.84 0.75
9. I have difficulty speaking due to
my myasthenia gravis.
9. Eu tenho dificuldade para falar por causa da
Miastenia Gravis.
1.8 (1.1) 2 (0-4) 0.73 0.75
10. I have trouble driving due to my
myasthenia gravis.
10. Eu tenho problemas para dirigir por causa da
Miastenia Gravis.
1.3 (1.3) 1.5 (0-3) 0.08 0.77
11. I am depressed about my
myasthenia gravis.
11. Eu estou deprimido por causa da Miastenia
Gravis.
1 (1) 1 (0-3) 0.77 0.75
12. I have trouble walking due to my
myasthenia gravis.
12. Eu tenho dificuldade para andar por causa da
Miastenia Gravis.
1.9 (0.9) 2 (0-3) 0.77 0.75
13. I have trouble getting around
public places because of my
myasthenia gravis.
13. Eu tenho dificuldade de passear em lugares
pu´blicos por causa Miastenia Gravis.
2 (1.2) 2 (0-4) 0.91 0.74
14. I feel overwhelmed by my
myasthenia gravis.
14. Sinto-me sobrecarregado por causa da
Miastenia Gravis.
1.6 (1) 1 (0-4) 0.90 0.75
15. I have trouble performing my
personal grooming needs because of
myasthenia gravis.
15. Eu tenho dificuldade para realizar meus
cuidados pessoais (higiene) por causa da Miastenia
Gravis.
1.1 (0.7) 1 (0-3) 0.79 0.75
TOTAL: 23.8 (12.2) 21 (4-48) 1 0.95*
SD: standard deviation of the mean.
*Cronbach’s alpha coefficient
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multivariate linear regression analysis, and the regression
model retained all of the factors. An adjusted coefficient
R2 of 0.48 was calculated; this value indicates that the model
explains nearly half of the variance in QoL among MG
patients (Table 5).
’ DISCUSSION
Several studies have observed that MG worsens the QoL
of people suffering from this disorder. However, few studies
have used disease-specific instruments and QoL has not been
investigated previously in Brazilian MG patients.
MG-QOL15 was developed from MG-QOL60 and it has
been thoroughly evaluated regarding its reliability, validity and
usefulness (10-13). The Brazilian version of MG-QOL15 has
shown good internal consistency and concurrent validity with
SF-36. A low item-total correlation for item 10 (‘‘I have trouble
driving’’) probably resulted from the presence of non-drivers in
the sample. The Japanese version of MG-QOL15 also found
low item-total correlation for item 10 due to heavy traffic and
the high cost of parking spaces in the Tokyo metropolitan area
(21). Analysis of the correlation between MG-QOL15 and the
domains of SF-36 revealed that only the pain domain does not
correlate with MG-QOL15. This finding is expected, as muscle
pain is not frequent in MG patients. Notably, when pain is
present, it significantly impacts QoL (22,23).
The mean scores on MG-QOL15 and SF-36 suggest good
perception of physical, psychological and social well-being
among MG patients. In line with this finding, Paul et al.
previously observed that QoL and well-being measures were
not significantly different between MG patients and the
general population (9).
The current study did not reveal any association between
QoL and MGFA classification of the disease, which reflects the
worst episode of MG during a patient’s life. However, MG-
QOL15 positively correlated with MGC, a measure of current
disease severity. This result corroborates the view that the
MGFA classification does not actually reflect current clinical
severity or associated QoL (15). The negative correlation
between the severity of current MG symptoms and QoL has
been well established in the literature (12,16). The disease
duration did not influence perceived QoL among MG patients
due to the fluctuating nature of MG symptoms. Accordingly,
patients with a longer disease duration did not necessarily have
more symptoms or poorer QoL. There is evidence that as the
disease duration increases, patients are more likely to
experience remission of MG signs and symptoms (24).
Although some reports described that the mental health
component of SF-36 is not significantly affected in MG
patients, other reports suggested that the QoL of MG
patients is similarly affected by physical and mental health
factors (6,8,9). In the current study, the levels of anxiety and
depression negatively correlated with QoL. As patients with
MG have an elevated frequency of psychiatric disorders,
particularly depression and anxiety, psychological symptoms
must not be overlooked in clinical practice (25). Importantly,
these symptoms typically predict poorer QoL both in the
general population and among patients with other neurolo-
gical disorders (6,26).
Regarding treatment, prednisone and pyridostigmine were
the most commonly used treatments; this result is similar to
the findings reported in the literature (21,27,28). A negative
correlation was observed between QoL and the current
dosage of prednisone. It is uncertain whether this correlation
is due to the side effects of prednisone or to the association of
a higher prednisone dosage with increased MG severity (28).
There was no difference in QoL between thymectomized and
non-thymectomized patients; this observation was consistent
with the findings of other studies (28-30).
Future studies must investigate how variables not
included in this study may impact QoL, coping strategies
and resilience among MG patients. Follow-up studies may
Table 3 - Correlation of the score on the Brazilian-Portuguese
version of MG-QOL15 with the scores on SF-36 and its domains.
Continuous variables Rho p-value
SF-36 -0.63** o0.01
SF-36 Physical Function -0.45** o0.01
SF-36 Role—Physical -0.75** o0.01
SF-36 Bodily Pain -0.12 0.32
SF-36 General Health -0.46** o0.01
SF-36 Vitality -0.46** o0.01
SF-36 Social Functioning -0.24* 0.04
SF-36 Role—Emotional -0.23* 0.04
SF-36 Mental Health -0.22 0.06
Table 4 - Analyses of the associations and correlations between
dependent variables (patient background and clinical factors) and
the scores on the Brazilian-Portuguese version of MG-QOL15.
Variables Rho or Z p-value
Gender -0.14* 0.87
First symptom o0.01** 0.76
Main symptom o0.01** 0.23
MGFA Classification o0.01*** 0.29
Thymectomy -0.81* 0.41
Myasthenic crisis -0.81* 0.41
Age -0.01 0.88
Treatment time 0.06 0.60
MGC 0.60 o0.01
Pyridostigmine (dose) -0.14 0.22
Prednisone (dose) 0.36 o0.01
Azathioprine (dose) 0.01 0.90
HAD Anxiety subscale score 0.38 o0.01
HAD Depression subscale score 0.45 o0.01
Abbreviations: MGC: Myasthenia Gravis Composite; HAD: Hospital
Anxiety and Depression.
Tests used: Pearson’s correlation (parametric continuous variables); Z score
(normality test); * Mann-Whitney U test (nonparametric categorical
variables - two variables); ** Kruskal-Wallis test (non-parametric
categorical variables - three variables); *** one-way ANOVA (parametric
categorical variables - three variables).
Table 5 - Multivariate linear regression analysis of MG-QOL15
scores representing the effect of each independent variable on
QoL.
Continuous variables B
coefficient
p-
value
95% confidence
interval
MGC 0.93 o0.01 0.45 – 1.41
Prednisone (dose) 0.12 0.04 0.03 – 0.24
HAD Anxiety subscale
score
0.77 0.03 0.05 – 1.49
HAD Depression subscale
score
0.69 o0.01 0.18 – 1.21
MGC: Myasthenia Gravis Composite; HAD: Hospital Anxiety and
Depression.
Test used: Automatic Linear Modeling
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overcome the limitation of the cross-sectional design of the
current study and may enable causal assumptions.
In conclusion, this study provides evidence that the
Brazilian version of MG-QOL15 is a valid and reliable
instrument. Disease severity, anxiety level, depression level
and prednisone dosage were negatively associated with the
QoL of MG patients. Physicians must be aware of these
determinants of poorer QoL, as most of these factors are
clinically manageable.
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